Veliparib for the treatment of ovarian cancer

Research output: Contribution to journalArticle

Abstract

Ovarian cancer represents the sixth most commonly diagnosed cancer among women, with an incidence of 6.1 cases per 100.000 women and a cumulative lifetime risk of 0.5%. Treatment is based on debulking surgery and platinum-based chemotherapy, with the potential combination with taxane. However, the recently available data on the genetic basis and aetiology of ovarian cancer has led to the development of new anticancer drugs. Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most promising new classes of targeted agents currently under investigation for the treatment of ovarian cancer. Veliparib is a small molecule that inhibits both PARP-1 and PARP-2 and was originally shown to be efficacious in BRCA-associated tumors.Areas covered: This manuscript reviews the Phase I and II studies investigating the use of veliparib in ovarian cancer. This article also provides and discusses the pharmacokinetics and pharmacodynamics of veliparib.Expert opinion: It is still being discussed whether PARP inhibitors should be used in a front-line or relapsed setting, alone or in combination with cytotoxic chemotherapy or as maintenance treatment. In terms of veliparib, further investigations are needed to explore its full potential in ovarian cancer. It is hoped that the ongoing phase 3 trials will help to further elucidate it potential as a treatment option.

Original languageEnglish
Pages (from-to)367-374
Number of pages8
JournalExpert Opinion on Investigational Drugs
Volume25
Issue number3
DOIs
Publication statusPublished - Mar 3 2016

Fingerprint

Ovarian Neoplasms
Therapeutics
Drug Therapy
Poly(ADP-ribose) Polymerases
Expert Testimony
Platinum
Neoplasms
Pharmacokinetics
veliparib
Incidence
Pharmaceutical Preparations
Poly(ADP-ribose) Polymerase Inhibitors

Keywords

  • chemotherapy
  • ovarian cancer therapy
  • PARP inhibitors
  • Veliparib

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Veliparib for the treatment of ovarian cancer. / Bogliolo, Stefano; Cassani, Chiara; Dominoni, Mattia; Musacchi, Valentina; Venturini, Pierluigi; Spinillo, Arsenio; Ferrero, Simone; Gardella, Barbara.

In: Expert Opinion on Investigational Drugs, Vol. 25, No. 3, 03.03.2016, p. 367-374.

Research output: Contribution to journalArticle

@article{7cb3f61c67cb4546842db90ae22a9d2e,
title = "Veliparib for the treatment of ovarian cancer",
abstract = "Ovarian cancer represents the sixth most commonly diagnosed cancer among women, with an incidence of 6.1 cases per 100.000 women and a cumulative lifetime risk of 0.5{\%}. Treatment is based on debulking surgery and platinum-based chemotherapy, with the potential combination with taxane. However, the recently available data on the genetic basis and aetiology of ovarian cancer has led to the development of new anticancer drugs. Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most promising new classes of targeted agents currently under investigation for the treatment of ovarian cancer. Veliparib is a small molecule that inhibits both PARP-1 and PARP-2 and was originally shown to be efficacious in BRCA-associated tumors.Areas covered: This manuscript reviews the Phase I and II studies investigating the use of veliparib in ovarian cancer. This article also provides and discusses the pharmacokinetics and pharmacodynamics of veliparib.Expert opinion: It is still being discussed whether PARP inhibitors should be used in a front-line or relapsed setting, alone or in combination with cytotoxic chemotherapy or as maintenance treatment. In terms of veliparib, further investigations are needed to explore its full potential in ovarian cancer. It is hoped that the ongoing phase 3 trials will help to further elucidate it potential as a treatment option.",
keywords = "chemotherapy, ovarian cancer therapy, PARP inhibitors, Veliparib",
author = "Stefano Bogliolo and Chiara Cassani and Mattia Dominoni and Valentina Musacchi and Pierluigi Venturini and Arsenio Spinillo and Simone Ferrero and Barbara Gardella",
year = "2016",
month = "3",
day = "3",
doi = "10.1517/13543784.2016.1146677",
language = "English",
volume = "25",
pages = "367--374",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Veliparib for the treatment of ovarian cancer

AU - Bogliolo, Stefano

AU - Cassani, Chiara

AU - Dominoni, Mattia

AU - Musacchi, Valentina

AU - Venturini, Pierluigi

AU - Spinillo, Arsenio

AU - Ferrero, Simone

AU - Gardella, Barbara

PY - 2016/3/3

Y1 - 2016/3/3

N2 - Ovarian cancer represents the sixth most commonly diagnosed cancer among women, with an incidence of 6.1 cases per 100.000 women and a cumulative lifetime risk of 0.5%. Treatment is based on debulking surgery and platinum-based chemotherapy, with the potential combination with taxane. However, the recently available data on the genetic basis and aetiology of ovarian cancer has led to the development of new anticancer drugs. Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most promising new classes of targeted agents currently under investigation for the treatment of ovarian cancer. Veliparib is a small molecule that inhibits both PARP-1 and PARP-2 and was originally shown to be efficacious in BRCA-associated tumors.Areas covered: This manuscript reviews the Phase I and II studies investigating the use of veliparib in ovarian cancer. This article also provides and discusses the pharmacokinetics and pharmacodynamics of veliparib.Expert opinion: It is still being discussed whether PARP inhibitors should be used in a front-line or relapsed setting, alone or in combination with cytotoxic chemotherapy or as maintenance treatment. In terms of veliparib, further investigations are needed to explore its full potential in ovarian cancer. It is hoped that the ongoing phase 3 trials will help to further elucidate it potential as a treatment option.

AB - Ovarian cancer represents the sixth most commonly diagnosed cancer among women, with an incidence of 6.1 cases per 100.000 women and a cumulative lifetime risk of 0.5%. Treatment is based on debulking surgery and platinum-based chemotherapy, with the potential combination with taxane. However, the recently available data on the genetic basis and aetiology of ovarian cancer has led to the development of new anticancer drugs. Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most promising new classes of targeted agents currently under investigation for the treatment of ovarian cancer. Veliparib is a small molecule that inhibits both PARP-1 and PARP-2 and was originally shown to be efficacious in BRCA-associated tumors.Areas covered: This manuscript reviews the Phase I and II studies investigating the use of veliparib in ovarian cancer. This article also provides and discusses the pharmacokinetics and pharmacodynamics of veliparib.Expert opinion: It is still being discussed whether PARP inhibitors should be used in a front-line or relapsed setting, alone or in combination with cytotoxic chemotherapy or as maintenance treatment. In terms of veliparib, further investigations are needed to explore its full potential in ovarian cancer. It is hoped that the ongoing phase 3 trials will help to further elucidate it potential as a treatment option.

KW - chemotherapy

KW - ovarian cancer therapy

KW - PARP inhibitors

KW - Veliparib

UR - http://www.scopus.com/inward/record.url?scp=84959108834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959108834&partnerID=8YFLogxK

U2 - 10.1517/13543784.2016.1146677

DO - 10.1517/13543784.2016.1146677

M3 - Article

VL - 25

SP - 367

EP - 374

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 3

ER -